Skip to search formSkip to main contentSkip to account menu

L19-IL2 Monoclonal Antibody-Cytokine Fusion Protein

Known as: L19-IL2 
An immunoconjugate consisting of the recombinant form of the cytokine interleukin-2 (IL-2) fused to a human single-chain Fv (scFv) antibody fragment… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
ABSTRACT Recently, we have shown that the administration of the tumour-targeted antibody-based immunocytokine L19-IL2 after… 
Highly Cited
2015
Highly Cited
2015
Abstract The intratumoral injection of cytokines, in particular IL2, has shown promise for cutaneous melanoma patients with… 
Review
2014
Review
2014
Advances in the understanding of tumor immunology and molecular biology of melanoma cells have favored a larger application of… 
Highly Cited
2013
Highly Cited
2013
Systemic high-dose IL2 promotes long-term survival in a subset of metastatic melanoma patients, but this treatment is accompanied… 
Highly Cited
2011
Highly Cited
2011
Purpose: L19-IL2 is an immunocytokine composed of an antibody fragment specific to the EDB domain of fibronectin, a tumor… 
Highly Cited
2010
Highly Cited
2010
L19‐IL2 and L19TNFα are fusion proteins composed of L19(scFv), specific for the angiogenesis‐associated ED‐B containing… 
Highly Cited
2009
Highly Cited
2009
The antibody-mediated delivery of therapeutic agents to sites of angiogenesis is an attractive strategy for anticancer therapy… 
Highly Cited
2008
Highly Cited
2008
Purpose: Effective control of pancreatic cancer has been hampered primarily by the lack of tumor specificity of current treatment…